Rapporto annuale 2004 - Istituto di Ricerche Farmacologiche Mario ...

Pharma Mar USA, Inc.
Policlinico di Padova / C.O.R.
PTC Pharma AG
Regione Veneto
Sara Bet srl
SENDO-Tech Srl
Sigma-tau SpA
Università degli Studi di Padova
SELEZIONE PUBBLICAZIONI SCIENTIFICHE APPARSE
NELL'ANNO 2004
IRFMN
N. Celli, B. Mariani, F. Di Carlo, M. Zucchetti, L. Lopez-Lazaro, M. D’Incalci, D. Rotilio. Determination of Aplidin,
a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with
electrospray ionisation tandem mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis, 34:
619-630 (2004).
Tognon G., Frapolli G., Zaffaroni M., Erba E., Zucchetti M., Faircloth G.T., M. D’Incalci, Fetal bovine serum, but
not human serum inhibits the in vitro cytotoxicity of ET-743 (Yondelis TM; trabectedin). An example of potential
problems for extrapolation of active drug concentrations from in vitro studies. Cancer Chemother Pharmacol., 53(1):
89-90 (2004).
Janossy J., Ubezio P., Apati A., Magocsi M., Tompa P., Friedrich P. Calpain as a multi-site regulator of cell cycle.
Biochem. Pharmacol., 67:1513-1521 (2004).
Erba E., Cavallaro E., Damia G., Mantovani R., Di Silvio A, Di Francesco A.M., Riccardi R., Cuevas C., Faircloth
G.T., D’Incalci M. The unique biological features of the marine product Yondelis TM (ET-743, Trabectedin) are
shared by its analog ET-637, which lacks the C ring. Oncology Research, 14: 579-587 (2004).
Lupi M., Matera G., Branduardi D., D’Incalci M., Ubezio P., Cytostatic and cytotoxic effects of topotecan decoded
by a novel mathematical simulation approach. Cancer Research, 64: 2825-2832 (2004).
Matera G., Lupi M., Ubezio P., Heterogeneous cell response to Topotecan in a CFSE-based proliferation test.
Cytometry, Part A, 62A:118-128 (2004).
Donald S., Verschoyle, R.D., Greaves P., Colombo T., Zucchetti M., Falcioni C., Zaffaroni M., D’Incalci M.,
Manson M.M., Jimeno J., Steward W.P., Gescher A.J. Dietary Agent Indole-3-Carbinol Protects Female Rats Against
the Hepatotoxicity of the Antitumor Drug ET-743 (Trabectidin) Without Compromising Efficacy in a Rat Mammary
Carcinoma. Int. J. Cancer, 111, 961-967 (2004).
C. Sottani, M Zucchetti, M. Zaffaroni, M. Bettinelli, C. Minoia. Validated procedure for simultaneous trace level
determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high performance liquid
chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom, 18(10): 1017-1023 (2004).
P. Ubezio. Unraveling the complexity of cell cycle effects of anticancer drugs in cell populations. Discrete and
Continuous Dynamical Systems- Series B, 4(1):323-335 (2004).
M. D’Incalci, R. Dulbecco. Introduction to the special issue “Gene transcription and cancer, from the Genome Project
to practical achievements in diagnosis and therapy”. Eur. J. Cancer, 40(17): 2535-2632 (2004).
D’Incalci M., Simone M., Tavecchio M., Damia G., Garbi A., Erba E. New Drugs from the Sea. J. Chemother.,
16(4): 86-89 (2004).
Marchini S., D’Incalci M., Broggini M. New molecules and strategies in the field of anticancer agents. Curr. Med.
Chem. -Anti-Cancer Agents, 4:247-262 (2004).
Piccolo E., Vignati S., Maffucci T., Innominato P. F., Riley A. M., Potter B. V. L., Pandolfi P.P., Broggini M.,
17
RAPPORTO ATTIVITA’ 2004